Co-CEO Han Aiden named insider at Zhengye Biotechnology (ZYBT) in Form 3

Rhea-AI Filing Summary

Zhengye Biotechnology Holding Ltd filed an initial statement of beneficial ownership on Form 3 for Han Aiden, who serves as Co-Chief Executive Officer. The filing does not list any specific holdings or report any stock transactions, and instead establishes Han Aiden as a reporting insider for future disclosures.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Han Aiden

(Last) (First) (Middle)

NO.1 LIANMENG ROAD

(Street)

JILIN CITY, JILIN PROVINCE 132101

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Zhengye Biotechnology Holding Ltd [ ZYBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Aiden Han	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Zhengye Biotechnology (ZYBT) Form 3 filing report?

The Form 3 filing reports the initial insider status of Co-Chief Executive Officer Han Aiden at Zhengye Biotechnology Holding Ltd. It serves as a baseline disclosure of insider status, without detailing any specific shareholdings or transactions at this time.

Who is identified as an insider in Zhengye Biotechnology (ZYBT) Form 3?

The Form 3 identifies Han Aiden as an insider of Zhengye Biotechnology Holding Ltd. He is reported as an officer of the company, holding the role of Co-Chief Executive Officer, which triggers ongoing reporting obligations under SEC rules.

Does the Zhengye Biotechnology (ZYBT) Form 3 show any share transactions?

The Form 3 for Zhengye Biotechnology Holding Ltd shows no reported share transactions. Transaction counts and share amounts for buying, selling, exercises, gifts, and other actions are all zero, indicating the filing is purely an initial ownership statement.

Are any stock options or derivatives disclosed in the Zhengye Biotechnology (ZYBT) Form 3?

The Form 3 discloses no derivative positions for Co-Chief Executive Officer Han Aiden. The derivative summary is empty and derivative transaction counts are zero, meaning no options, warrants, or similar instruments are reported in this initial filing.

What is the significance of this Zhengye Biotechnology (ZYBT) Form 3 for investors?

This Form 3 formally designates Han Aiden as a reporting insider at Zhengye Biotechnology Holding Ltd. While it contains no transactions, it sets the foundation for future Forms 4 or 5 that will detail any changes in his beneficial ownership of company securities.